Do you have Type 2 Diabetes and kidney problems?

The FIGARO-DKD study – a clinical trial to investigate the use of finerenone, a new drug under development for the treatment of diabetic kidney disease

The purpose of the FIGARO-DKD clinical research study is to evaluate whether adding an investigational medication called finerenone to regular treatment is safe and effective to help reduce cardiovascular complications like heart disease or stroke in patients with type 2 diabetes and diabetic kidney disease.

The study will also look at whether the addition of finerenone to regular treatment may help slow the progression of kidney disease.

Anticipated date that enrolment will close: June 2018

Who can take part

People who meet the following criteria may be eligible to be part of the study:

  • People with type 2 diabetes
  • People with Diabetic Kidney Disease (confirmed with blood and urine tests)
  • Currently taking medication for high blood pressure
  • If you are aged over 18

What is involved for you

  • Blood and urine samples
  • Echocardiograms
  • Weight
  • Questionnaires
check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4

For more information

Quote reference number
2015.210
Marika Bjorasen
+613 9342 7344
Danielle West
+613 9342 7344